Medtentia (Finland)

Medtentia (Finland) is a cardiovascular device company based in Espoo, Finland, according to Wikidata. The company is associated with the development of transcatheter mitral valve repair technology, and its commercial activities are presented publicly under the HVR Cardio name. HVR Cardio describes itself as a cardiovascular device company developing breakthrough solutions for mitral valve repair based on its proprietary HELIX technology. The company's flagship technology is the CathHELIX Transcatheter Mitral Repair Technology. According to the company, CathHELIX transforms the standard for surgical mitral valve repair into a transcatheter approach. The system is designed to reduce the mitral annulus and deploy a self-securing ring to the atrial and ventricular sides, reshaping the annulus and restoring native leaflet function. HVR Cardio positions CathHELIX as a potential first-line therapy for mitral valve regurgitation. The company states that the procedure can reduce or eliminate mitral valve regurgitation, provide annular stabilization with the CathHELIX implant to support positive ventricular remodeling, restore and maintain native leaflet function, leave future treatment options open, and expand the toolbox for minimally invasive mitral valve repair. The company's stated mission is to develop solutions for mitral valve interventions that are fast, easy to use, and less invasive while enhancing clinical efficacy. Its stated goal is to provide structural interventionalists a first-line mitral valve repair option to treat the root cause of mitral valve regurgitation, annular dilation. HVR Cardio says it is dedicated to expanding transcatheter mitral valve treatment choices by transforming the standard for surgical mitral valve repair into a transcatheter approach. Medtentia (Finland) is headquartered in Espoo, Finland. The company operates in the cardiovascular medical device sector, with a focus on structural heart interventions and mitral valve repair. Its technology targets the structural heart field using a familiar catheter-based procedure, and the company believes CathHELIX has the potential to be a first-line therapy that expands the treatable patient population.

Medtentia (Finland) is a company based in Espoo, Finland, according to Wikidata. The company is associated with the development of transcatheter mitral valve repair technology, and its commercial activities are presented publicly under the HVR Cardio name. HVR Cardio describes itself as a cardiovascular device company developing breakthrough solutions for mitral valve repair based on its proprietary HELIX technology. The company's central technology is the CathHELIX Transcatheter Mitral Repair Technology. According to HVR Cardio, CathHELIX transforms the standard for surgical mitral valve repair into a transcatheter approach. The system is designed to reduce the mitral annulus and deploy a self-securing ring to the atrial and ventricular sides, reshaping the annulus and restoring native leaflet function. HVR Cardio states that the CathHELIX system uses a familiar transcatheter approach and a user-friendly delivery device, with the unique self-fixating HELIX ring readily anchored into place to support the atrial and ventricular sides of the annulus. The company positions the technology as a potential first-line therapy that could expand the treatable patient population. The company's stated mission is to develop solutions for mitral valve interventions that are fast, easy to use, and less invasive while enhancing clinical efficacy. Its stated goal is to provide structural interventionalists a first-line mitral valve repair option to treat the root cause of mitral valve regurgitation, annular dilation. HVR Cardio says it is dedicated to expanding transcatheter mitral valve treatment choices by transforming the standard for surgical mitral valve repair into a transcatheter approach. Medtentia (Finland) operates in the cardiovascular medical device sector, with a focus on structural heart interventions and mitral valve repair. The company is headquartered in Espoo, Finland.

Developer of a transcatheter mitral valve repair system intended as a first-line therapy for mitral valve regurgitation.

• CathHELIX Transcatheter Mitral Repair Technology

  A transcatheter mitral repair system that reduces the mitral annulus and deploys a self-securing ring to the atrial and ventricular sides, reshaping the annulus and restoring native leaflet function.

• HELIX ring implant

  A self-fixating ring that is anchored into place to support the atrial and ventricular sides of the annulus.

1. 1HVR Cardiohvrcardio.com
2. 2About Us | HVR Cardiohvrcardio.com
3. 3Medtentia (Finland)wikidata.org